In contrast, our study reveals that the prognostic effect of BCL2 protein expression is time independent and BCL2 continues to be associated with favourable outcome over time, increasing its potential clinical value given the frequent occurrence of late relapses (particularly in ER+ breast cancer). The gene discussed is BCL2; the disease is breast cancer.